Who
Jon Marc Wigginton
Director
Company insider
Files Form 4 as: Director, Sutro Biopharma; Director, Checkmate Pharmaceuticals; Chief Medical Officer, Cullinan Therapeutics; Sr VP, Clinical Dev. & CMO, MacroGenics.
In numbers
- Trades disclosed
- 81
- Buys
- 0
- Sells
- 21
- Bought
- $0
- Sold
- $4.4M
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 1 Apr 2014
- Last trade
- 5 Jun 2026
- Last filed
- 9 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Jun 2026filed 9 Jun 2026 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 23 Dec 2025filed 29 Dec 2025 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,500 at $0.00 | filing |
| 6 Jun 2025filed 10 Jun 2025 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 6 Jun 2024filed 10 Jun 2024 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 8 Jun 2023filed 12 Jun 2023 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 6 Jun 2022filed 8 Jun 2022 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,500 at $0.00 | filing |
| 31 May 2022filed 31 May 2022 | Checkmate Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —20,061 | filing |
| 30 Jan 2022filed 1 Feb 2022 | Checkmate Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —20,061 at $0.00 | filing |
| 3 Jun 2021filed 7 Jun 2021 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,500 at $0.00 | filing |
| 7 Jan 2021filed 11 Jan 2021 | CGEM Cullinan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —116,666 at $0.00 | filing |
| 30 Nov 2020filed 1 Dec 2020 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,000 at $0.00 | filing |
| 20 Feb 2020filed 24 Feb 2020 | MGNX MacroGenicsoption or derivative · Biotechnology | SEC FORM 4 Code A | $1.1M100,000 at $11.50 | filing |
| 21 Feb 2019filed 25 Feb 2019 | MGNX MacroGenicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,000 at $0.00 | filing |
| 2 Mar 2018filed 6 Mar 2018 | MGNX MacroGenicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —70,000 at $0.00 | filing |
| 26 Feb 2018filed 27 Feb 2018 | MGNX MacroGenicsBiotechnology | SEC FORM 4 Code F | $260K11,070 at $23.46 | filing |
| 17 Jan 2018filed 18 Jan 2018 | MGNX MacroGenicsBiotechnology | SEC FORM 4 Code M | $12K2,524 at $4.70 | filing |
| 17 Jan 2018filed 18 Jan 2018 | MGNX MacroGenicsBiotechnology | SEC FORM 4 Sold | $50K2,524 at $20.00 | filing |
| 17 Jan 2018filed 18 Jan 2018 | MGNX MacroGenicsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,524 at $0.00 | filing |
| 16 Jan 2018filed 18 Jan 2018 | MGNX MacroGenicsBiotechnology | SEC FORM 4 Code M | $12K2,476 at $4.70 | filing |
News
MacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with Advanced Solid TumorsMGNX · manilatimes.net · 15 Oct 2026Head-To-Head Contrast: Zenas BioPharma (NASDAQ:ZBIO) and MacroGenics (NASDAQ:MGNX)MGNX · themarketsdaily.com · 14 Oct 2026
0 headlines in the last 90 days name Jon Marc Wigginton; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.